JBS has landed on the wrong side of its August 10 print, falling more than 8.5% on the day and extending losses to roughly 4.3% on the week — and the question now is whether the defensive positioning that built through late July has fully unwound or is settling into something more persistent.
The earnings reaction delivered exactly what the cautious setup implied. The stock closed at $13.02 on Tuesday, down from $13.69 heading into the print, erasing much of the 9% monthly gain still visible in the trailing figures. Options remain more defensive than usual even after the event. The put/call ratio rose further to 0.13 — more than two standard deviations above its 20-day mean of 0.103 — the highest relative reading of the past 52 weeks outside a single isolated spike. Calls still dominate in absolute terms, but the direction of travel since late July has been uniformly toward hedging, and that hasn't reversed post-print. Short interest ticked up again on Tuesday, with borrowed shares reaching roughly 37.75 million, up about 4.4% on the week and 32% over the past month. Importantly, the borrow market is not strained: availability has tightened from above 500% a week ago to roughly 436% now — still firmly in normal territory, meaning there are more than four shares available to lend for every one currently borrowed. Cost to borrow remains negligible at 0.51%, down sharply from above 1.2% in early July. Shorts are adding exposure, but they're doing so cheaply and without any squeeze pressure to worry about.
The Street's reaction to the print has been swift and consistent in one direction. JP Morgan's Lucas Ferreira — who upgraded JBS to Overweight just two weeks ago on July 28 — trimmed his target from $18.00 to $17.50 on Wednesday while keeping the constructive rating. That follows a pattern: Barclays cut its target from $21 to $20 in mid-July, and both JP Morgan and Barclays had been lowering targets since May's downgrade-and-cut cycle. The consensus remains constructive — analyst recommendation divergence ranks in the 93rd percentile of the universe — but targets have been drifting lower even among the bulls. The stock's current price of $13.02 implies roughly 34% upside to the JP Morgan target, which is a wide gap that reflects either a genuine valuation opportunity or persistent concern about execution. At 9.9x trailing PE and 5.9x EV/EBITDA, the multiples are undemanding. The bull case rests on margin expansion — EBITDA margins roughly doubled between 2008–2012 and recent years — and brand momentum, particularly Just Bare and Pilgrim's. Bears point to livestock disease risk, commodity cost exposure, and currency headwinds from JBS's heavily emerging-market production base.
The ownership structure is worth noting briefly. Controlling shareholder J&F S.A. holds just over 50% of shares, meaning the free float is effectively less than half the total share count. Brazilian development bank BNDESPAR holds another 18.6%. Together, those two anchors own nearly 70% of the company, leaving institutional investors like Capital Research (4.1%), BlackRock (3.2%), and Davis Selected Advisers (2.5%) — which built a 14.4 million share position in recent months — competing for a relatively thin float. That structural tightness partly explains why even a moderate short position of 37.75 million borrowed shares generates visible movement in availability metrics.
The prior earnings print in May produced a similar outcome: JBS fell 8.4% on the day and 15.5% over the following five days. The August print has so far matched the day-one move almost exactly. With the next earnings event now pushed to November 9, the near-term data to watch is whether short interest continues building into the $13 level, and whether the options market's elevated put/call ratio normalises as the event premium unwinds — or holds at these elevated levels as traders reassess the broader commodity backdrop heading into autumn.
See the live data behind this article on ORTEX.
Open JBS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
